fibroblast growth factor 21 in migraine headache
Phase 2
Recruiting
- Conditions
- Migrain.Migraine
- Registration Number
- IRCT20190804044429N3
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients with recently migraine headache (with or without aura)
candidate receiving prophylaxis regimen with sodium valproate
Exclusion Criteria
Headache sub-types other than migraine
Pregnancy
Breast feeding
Renal and Liver dysfunction
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FGF-21 serum levels. Timepoint: on 0 and 48 days of the study. Method of measurement: Elisa kite.;Headache severity. Timepoint: On 0 and 48 days of the study. Method of measurement: VAS scale.
- Secondary Outcome Measures
Name Time Method Clinical response evaluation. Timepoint: On 0 and 48 days of the study. Method of measurement: MIDAS questionnaire.;Side effects profile. Timepoint: weekly. Method of measurement: history taking.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link FGF21 serum levels to migraine headache pathophysiology in sodium valproate-treated patients?
How does sodium valproate's effect on FGF21 compare to standard-of-care migraine therapies like triptans or CGRP inhibitors?
Are serum FGF21 levels a reliable biomarker for predicting response to sodium valproate in episodic or chronic migraine subtypes?
What adverse events are associated with sodium valproate-induced FGF21 modulation in migraine patients, and how are they managed?
What combination therapies or alternative FGF21-targeting compounds show promise in migraine treatment alongside sodium valproate?